Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...
Zacks Investment Research on MSN
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
Ahead of its Analyst Day event on Thursday, Moderna (MRNA) indicated ~10% revenue growth for next year and increased its outlook for year-end liquidity, following up to a $1.5B loan from Ares ...
Moderna (NASDAQ:MRNA) Stock, Option Chain Option chain shows key data for Moderna's stock options at various strike prices and expiration dates. Traders use this information to analyze potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results